Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Compass Therapeutics (CMPX) Cash & Equivalents (2023 - 2025)

Compass Therapeutics' Cash & Equivalents history spans 3 years, with the latest figure at $30.6 million for Q4 2025.

  • For Q4 2025, Cash & Equivalents fell 30.44% year-over-year to $30.6 million; the TTM value through Dec 2025 reached $30.6 million, down 30.44%, while the annual FY2025 figure was $30.6 million, 30.44% down from the prior year.
  • Cash & Equivalents for Q4 2025 was $30.6 million at Compass Therapeutics, down from $46.2 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $46.2 million in Q3 2025 and bottomed at $19.3 million in Q2 2023.
  • The 3-year median for Cash & Equivalents is $30.5 million (2023), against an average of $32.3 million.
  • The largest annual shift saw Cash & Equivalents soared 81.82% in 2024 before it plummeted 30.44% in 2025.
  • A 3-year view of Cash & Equivalents shows it stood at $24.2 million in 2023, then skyrocketed by 81.82% to $44.1 million in 2024, then crashed by 30.44% to $30.6 million in 2025.
  • Per Business Quant, the three most recent readings for CMPX's Cash & Equivalents are $30.6 million (Q4 2025), $46.2 million (Q3 2025), and $23.4 million (Q2 2025).